Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 3
1986 8
1987 19
1988 20
1989 28
1990 26
1991 23
1992 15
1993 22
1994 30
1995 20
1996 11
1997 13
1998 17
1999 11
2000 14
2001 10
2002 17
2003 15
2004 10
2005 10
2006 6
2007 11
2008 15
2009 5
2010 5
2011 7
2012 7
2013 8
2014 7
2015 11
2016 13
2017 5
2018 4
2019 9
2020 7
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

447 results
Results by year
Filters applied: . Clear all
Page 1
Histamine Type-2 Receptor Antagonists (H2 Blockers).
[No authors listed] [No authors listed] 2018 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643264 Free Books & Documents. Review.
The initial H2 blocker approved for use in the United States was cimetidine (1977), which was followed by ranitidine (1983), famotidine (1986), and nizatidine (1988). All four of these agents are available by prescription and as over-the-counter oral formulations. ...
The initial H2 blocker approved for use in the United States was cimetidine (1977), which was followed by ranitidine (1983), famotidine (198 …
Review article: the management of heartburn during pregnancy and lactation.
Thélin CS, Richter JE. Thélin CS, et al. Aliment Pharmacol Ther. 2020 Feb;51(4):421-434. doi: 10.1111/apt.15611. Epub 2020 Jan 17. Aliment Pharmacol Ther. 2020. PMID: 31950535 Review.
If symptoms persist, any of the H(2) RAs can be used except for nizatidine (due to foetal teratogenicity or harm in animal studies). ...
If symptoms persist, any of the H(2) RAs can be used except for nizatidine (due to foetal teratogenicity or harm in animal studies). …
Nizatidine.
[No authors listed] [No authors listed] 2018 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643707 Free Books & Documents. Review.
Nizatidine is a histamine type 2 receptor antagonist (H2 blocker) which is widely used for treatment of acid-peptic disease and heartburn. Nizatidine has been linked to rare instances of clinically apparent acute liver injury....
Nizatidine is a histamine type 2 receptor antagonist (H2 blocker) which is widely used for treatment of acid-peptic disease and heart
Gastrointestinal dysmotility disorders in critically ill dogs and cats.
Whitehead K, Cortes Y, Eirmann L. Whitehead K, et al. J Vet Emerg Crit Care (San Antonio). 2016 Mar-Apr;26(2):234-53. doi: 10.1111/vec.12449. Epub 2016 Jan 28. J Vet Emerg Crit Care (San Antonio). 2016. PMID: 26822390 Review.
Pharmacological interventions are instituted to promote gastric emptying and effective intestinal motility and prevention of complications. Promotility agents, including ranitidine/nizatidine, metoclopramide, erythromycin, and cisapride are the mainstays of therapy in smal …
Pharmacological interventions are instituted to promote gastric emptying and effective intestinal motility and prevention of complications. …
Nizatidine.
[No authors listed] [No authors listed] 2021 Feb 15. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. 2021 Feb 15. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. PMID: 30000299 Free Books & Documents. Review.
Because of the low levels of nizatidine in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. ...
Because of the low levels of nizatidine in breastmilk, amounts ingested by the infant are small and would not be expected to cause an …
[Nizatidine].
Romero M, Franzosi MG. Romero M, et al. Medicina (Firenze). 1989 Jan-Mar;9(1):93-6. Medicina (Firenze). 1989. PMID: 2567957 Review. Italian.
Nizatidine is a new H2-receptor antagonist, as potent as ranitidine. ...Published clinical trials are limited. Over 3800 patients who have been treated with nizatidine, 300 mg for up to eight weeks or 150 mg at night for a year, did not appear to have significantly
Nizatidine is a new H2-receptor antagonist, as potent as ranitidine. ...Published clinical trials are limited. Over 3800 patients who
Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.
Cohen S, Bueno de Mesquita M, Mimouni FB. Cohen S, et al. Br J Clin Pharmacol. 2015 Aug;80(2):200-8. doi: 10.1111/bcp.12619. Epub 2015 Jun 11. Br J Clin Pharmacol. 2015. PMID: 25752807 Free PMC article. Review.
Our search strategy included the following keywords: omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, rantidine, cimetidine, famotidine, nizatidine, domperidone, metoclopramide, betanechol, erythromycin, baclofen, alginate. ...
Our search strategy included the following keywords: omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, rantidine, cimetidin …
Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
Zhao F, Wang S, Liu L, Wang Y. Zhao F, et al. Int J Clin Pharmacol Ther. 2016 Oct;54(10):761-70. doi: 10.5414/CP202564. Int J Clin Pharmacol Ther. 2016. PMID: 27443665 Review.
Within the H2RA family, famotidine 80 mg per day (OR = 0.17, 95% CI: 0.06 - 0.38) was determined to be the most effective, followed by famotidine 40 mg per day (odds ratio (OR) = 0.23, 95% confidence interval (CI), 0.11 - 0.44); ranitidine 1,200 mg per day (OR, 0.32; 95% CI, 0.13 …
Within the H2RA family, famotidine 80 mg per day (OR = 0.17, 95% CI: 0.06 - 0.38) was determined to be the most effective, followed by famot …
Effectiveness of Pharmacologic Interventions in the Management of Weight Gain in Patients With Severe Mental Illness: A Systematic Review and Meta-Analysis.
Hiluy JC, Nazar BP, Gonçalves WS, Coutinho W, Appolinario JC. Hiluy JC, et al. Prim Care Companion CNS Disord. 2019 Dec 19;21(6):19r02483. doi: 10.4088/PCC.19r02483. Prim Care Companion CNS Disord. 2019. PMID: 31856432 Free article.
RESULTS: The most-studied agent was metformin (14 studies), followed by topiramate (6 studies), nizatidine (4 studies), and sibutramine (3 studies). Other agents were investigated in 1 or 2 isolated studies. ...
RESULTS: The most-studied agent was metformin (14 studies), followed by topiramate (6 studies), nizatidine (4 studies), and sibutrami …
447 results